Cargando…
Tolerability of neoadjuvant chemotherapy for esophageal cancer in elderly patients over 76 years of age
Although the Japan Clinical Oncology Group trial demonstrated that neoadjuvant chemotherapy (NAC) with 5-fluorouracil plus cis-diamminedichloroplatinum had significant survival benefits, it excluded elderly patients aged ≥ 76 years. Therefore, our study aimed to evaluate the tolerability of NAC in e...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nagoya University
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9350567/ https://www.ncbi.nlm.nih.gov/pubmed/35967940 http://dx.doi.org/10.18999/nagjms.84.2.388 |
_version_ | 1784762246160711680 |
---|---|
author | Suzuki, Takafumi Ishibashi, Yusuke Tsujimoto, Hironori Sugasawa, Hidekazu Wakamatsu, Kotaro Kouzu, Keita Itazaki, Yujiro Sugihara, Takao Harada, Manabu Ito, Nozomi Kishi, Yoji Ueno, Hideki |
author_facet | Suzuki, Takafumi Ishibashi, Yusuke Tsujimoto, Hironori Sugasawa, Hidekazu Wakamatsu, Kotaro Kouzu, Keita Itazaki, Yujiro Sugihara, Takao Harada, Manabu Ito, Nozomi Kishi, Yoji Ueno, Hideki |
author_sort | Suzuki, Takafumi |
collection | PubMed |
description | Although the Japan Clinical Oncology Group trial demonstrated that neoadjuvant chemotherapy (NAC) with 5-fluorouracil plus cis-diamminedichloroplatinum had significant survival benefits, it excluded elderly patients aged ≥ 76 years. Therefore, our study aimed to evaluate the tolerability of NAC in elderly patients with esophageal cancer. Classified 174 patients with clinical stage II/III esophageal cancer who underwent esophagectomy from 2010 to 2020 into the E (aged ≥ 76 years; 55 patients) and Y (aged < 76; 119 patients) groups, and retrospectively investigated for clinicopathological findings, tolerability of NAC, relative dose intensity (RDI) and short- and long-term result. Patients who received NAC were fewer in the E group than in the Y group (51% vs 77%, p = 0.001). The E group had relatively lower completion rate of NAC (71% vs 85%, p = 0.116) and significantly lower mean RDI of 5-fluorouracil and cis-diamminedichloroplatinum than the Y group (73% vs 89%, p < 0.001). However, histological and radiological were comparable between both groups. Severe adverse events (grade ≥ 3) were relatively frequent (E, 42.9%; Y, 27.5%, p = 0.091), especially, neutropenia was significantly more frequent in the E group (25.0% vs 7.7%, p = 0.022). There were no differences in the incidence of postoperative complications between with and without NAC in both E and Y groups. Elderly patients with esophageal cancer might be more susceptible to toxicity of NAC. Hence, adequate case selection and careful of dose reduction are needed for elderly with esophageal cancer. |
format | Online Article Text |
id | pubmed-9350567 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nagoya University |
record_format | MEDLINE/PubMed |
spelling | pubmed-93505672022-08-11 Tolerability of neoadjuvant chemotherapy for esophageal cancer in elderly patients over 76 years of age Suzuki, Takafumi Ishibashi, Yusuke Tsujimoto, Hironori Sugasawa, Hidekazu Wakamatsu, Kotaro Kouzu, Keita Itazaki, Yujiro Sugihara, Takao Harada, Manabu Ito, Nozomi Kishi, Yoji Ueno, Hideki Nagoya J Med Sci Original Paper Although the Japan Clinical Oncology Group trial demonstrated that neoadjuvant chemotherapy (NAC) with 5-fluorouracil plus cis-diamminedichloroplatinum had significant survival benefits, it excluded elderly patients aged ≥ 76 years. Therefore, our study aimed to evaluate the tolerability of NAC in elderly patients with esophageal cancer. Classified 174 patients with clinical stage II/III esophageal cancer who underwent esophagectomy from 2010 to 2020 into the E (aged ≥ 76 years; 55 patients) and Y (aged < 76; 119 patients) groups, and retrospectively investigated for clinicopathological findings, tolerability of NAC, relative dose intensity (RDI) and short- and long-term result. Patients who received NAC were fewer in the E group than in the Y group (51% vs 77%, p = 0.001). The E group had relatively lower completion rate of NAC (71% vs 85%, p = 0.116) and significantly lower mean RDI of 5-fluorouracil and cis-diamminedichloroplatinum than the Y group (73% vs 89%, p < 0.001). However, histological and radiological were comparable between both groups. Severe adverse events (grade ≥ 3) were relatively frequent (E, 42.9%; Y, 27.5%, p = 0.091), especially, neutropenia was significantly more frequent in the E group (25.0% vs 7.7%, p = 0.022). There were no differences in the incidence of postoperative complications between with and without NAC in both E and Y groups. Elderly patients with esophageal cancer might be more susceptible to toxicity of NAC. Hence, adequate case selection and careful of dose reduction are needed for elderly with esophageal cancer. Nagoya University 2022-05 /pmc/articles/PMC9350567/ /pubmed/35967940 http://dx.doi.org/10.18999/nagjms.84.2.388 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ). |
spellingShingle | Original Paper Suzuki, Takafumi Ishibashi, Yusuke Tsujimoto, Hironori Sugasawa, Hidekazu Wakamatsu, Kotaro Kouzu, Keita Itazaki, Yujiro Sugihara, Takao Harada, Manabu Ito, Nozomi Kishi, Yoji Ueno, Hideki Tolerability of neoadjuvant chemotherapy for esophageal cancer in elderly patients over 76 years of age |
title | Tolerability of neoadjuvant chemotherapy for esophageal cancer in elderly patients over 76 years of age |
title_full | Tolerability of neoadjuvant chemotherapy for esophageal cancer in elderly patients over 76 years of age |
title_fullStr | Tolerability of neoadjuvant chemotherapy for esophageal cancer in elderly patients over 76 years of age |
title_full_unstemmed | Tolerability of neoadjuvant chemotherapy for esophageal cancer in elderly patients over 76 years of age |
title_short | Tolerability of neoadjuvant chemotherapy for esophageal cancer in elderly patients over 76 years of age |
title_sort | tolerability of neoadjuvant chemotherapy for esophageal cancer in elderly patients over 76 years of age |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9350567/ https://www.ncbi.nlm.nih.gov/pubmed/35967940 http://dx.doi.org/10.18999/nagjms.84.2.388 |
work_keys_str_mv | AT suzukitakafumi tolerabilityofneoadjuvantchemotherapyforesophagealcancerinelderlypatientsover76yearsofage AT ishibashiyusuke tolerabilityofneoadjuvantchemotherapyforesophagealcancerinelderlypatientsover76yearsofage AT tsujimotohironori tolerabilityofneoadjuvantchemotherapyforesophagealcancerinelderlypatientsover76yearsofage AT sugasawahidekazu tolerabilityofneoadjuvantchemotherapyforesophagealcancerinelderlypatientsover76yearsofage AT wakamatsukotaro tolerabilityofneoadjuvantchemotherapyforesophagealcancerinelderlypatientsover76yearsofage AT kouzukeita tolerabilityofneoadjuvantchemotherapyforesophagealcancerinelderlypatientsover76yearsofage AT itazakiyujiro tolerabilityofneoadjuvantchemotherapyforesophagealcancerinelderlypatientsover76yearsofage AT sugiharatakao tolerabilityofneoadjuvantchemotherapyforesophagealcancerinelderlypatientsover76yearsofage AT haradamanabu tolerabilityofneoadjuvantchemotherapyforesophagealcancerinelderlypatientsover76yearsofage AT itonozomi tolerabilityofneoadjuvantchemotherapyforesophagealcancerinelderlypatientsover76yearsofage AT kishiyoji tolerabilityofneoadjuvantchemotherapyforesophagealcancerinelderlypatientsover76yearsofage AT uenohideki tolerabilityofneoadjuvantchemotherapyforesophagealcancerinelderlypatientsover76yearsofage |